Treatment (Tx) sequencing with tepotinib in previously treated patients (pts) with MET exon 14 (METex14) skipping NSCLC in the VISION trial

被引：0
|
作者：
Viteri, S. [1 ]
Felip, E. [2 ]
Griesinger, F. [3 ]
Garassino, M. C. [4 ]
Sakai, H. [5 ]
Le, X. [6 ]
Veillon, R. [7 ]
Smit, E. F. [8 ]
Raskin, J. [9 ]
Thomas, M. [10 ,11 ,12 ]
Ahn, M-J. [13 ]
Vlassak, S. [14 ,15 ]
Bruns, R. [16 ]
Johne, A. [17 ]
Paik, P. K. [18 ]
机构：
[1] Dexeus Univ Hosp, Inst Oncol Dr Rosell, QuironSalud Grp, Barcelona, Spain
[2] Vall dHebron Inst Oncol VHIO, Dept Oncol, Barcelona, Spain
[3] Carl von Ossietzky Univ Oldenburg, Dept Hematol & Oncol, Pius Hosp, Oldenburg, Germany
[4] Univ Chicago, Sect Hematol Oncol, Dept Med, Knapp Ctr Biomed Discovery, Chicago, IL USA
[5] Ageo Cent Gen Hosp, Dept Thorac Oncol, Ageo, Japan
[6] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX USA
[7] CHU Bordeaux, Serv Malad Resp, Bordeaux, France
[8] Univ Med Ctr, Dept Pulm Dis, Leiden, Netherlands
[9] Antwerp Univ Hosp UZA, Dept Pulmonol & Thorac Oncol, Edegem, Belgium
[10] Univ Heidelberg Hosp, Thoraxklin & Natl Ctr Tumor Dis, Heidelberg, Germany
[11] Translat Lung Res Ctr Heidelberg TLRC H, Heidelberg, Germany
[12] German Ctr Lung Res DZL, Heidelberg, Germany
[13] Sungkyunkwan Univ, Dept Med, Sect Hematol Oncol, Samsung Med Ctr,Sch Med, Seoul, South Korea
[14] Global Med Affairs, Merck NVSA, Antwerp, Belgium
[15] Merck KGaA, Darmstadt, Germany
[16] Merck Healthcare KGaA, Depat Biostat, Darmstadt, Germany
[17] Merck Healthcare KGaA, Global Clin Dev, Darmstadt, Germany
[18] Mem Sloan Kettering Canc Ctr, Thorac Oncol Serv, New York, NY USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1380P
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Liquid biopsy to detect MET exon 14 skipping (METex14) and MET amplification in patients with advanced NSCLC: Biomarker analysis from VISION study
    Le, Xiuning
    Kowalski, Dariusz
    Cho, Byoung Chul
    Conte, Pierfranco
    Felip, Enriqueta
    Garassino, Marina Chiara
    Viteri, Santiago
    Chang, Gee-Chen
    Richart, John
    Paz-Ares, Luiz
    Juraeva, Dilafruz
    Straub, Josef
    Stroh, Christopher
    Paik, Paul
    CANCER RESEARCH, 2020, 80 (16)
  • [42] US health utility in advanced non-small cell lung cancer (NSCLC) patients harboring MET exon 14 (METex14) skipping mutations treated with tepotinib
    Paik, Paul K.
    Yang, Mo
    Knowles, Emma
    Hatswell, Anthony
    Vioix, Helene
    Liu, Frank Xiaoqing
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (28)
  • [43] Real-world next-generation sequencing (NGS) and treatment (Tx) patterns in non-small cell lung cancer (NSCLC) patients (pts) with MET exon 14 skipping mutations (METex14)
    Le, X.
    Martinalbo, J.
    Holynskyj, A.
    Rhodes, W. C.
    Wu, W-H.
    Kim, J.
    Pretre, V.
    Ye, F.
    Morrissette, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S988 - S988
  • [44] Liquid biopsies (LBx) and tissue biopsies (TBx) for identifying MET exon 14 (METex14) skipping in advanced NSCLC: Analyses from the phase II VISION study of tepotinib
    Rolfo, C. D.
    Grupp, A. M. OBrate
    Menzel, C.
    Bruns, R.
    Juraeva, D.
    Stroh, C.
    Johne, A.
    Paik, P. K.
    ANNALS OF ONCOLOGY, 2023, 34
  • [45] ABN401 in patients with NSCLC with MET exon 14 (METex14) skipping: Result from the pilot expansion study
    Lee, Dae Ho
    Han, Ji-Youn
    Lemech, Charlotte Rose
    Millward, Michael
    Roohullah, Aflah
    Choi, Jun Young
    Park, Kyung Eui
    Kim, Na Young
    Im, Sunyhe
    Rajasekaran, Nirmal
    Lee, Sangsuk
    Moon, Hanlim
    Hwang, Sunjin
    Shin, Youngkee
    Lee, Se-Hoon
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [46] Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management
    Veillon, Remi
    Sakai, Hiroshi
    Le, Xiuning
    Felip, Enriqueta
    Cortot, Alexis B.
    Smit, Egbert F.
    Park, Keunchil
    Griesinger, Frank
    Britschgi, Christian
    Wu, Yi-Long
    Melosky, Barbara
    Baijal, Shobhit
    de Castro Jr, Gilberto
    Sedova, Michaela
    Berghoff, Karin
    Otto, Gordon
    Paik, Paul K.
    CLINICAL LUNG CANCER, 2022, 23 (04) : 320 - 332
  • [47] NSCLC with METex14 Skipping Mutation Targeted Therapy with Tepotinib closes therapeutic Gap
    Warpakowski, Andrea
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (05)
  • [48] Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISION
    Kato, Terufumi
    Yang, James Chih-Hsin
    Ahn, Myung-Ju
    Sakai, Hiroshi
    Morise, Masahiro
    Chen, Yuh-Min
    Han, Ji-Youn
    Yang, Jin-Ji
    Zhao, Jun
    Hsia, Te-Chun
    Berghoff, Karin
    Bruns, Rolf
    Vioix, Helene
    Lang, Simone
    Johne, Andreas
    Le, Xiuning
    Paik, Paul K.
    BRITISH JOURNAL OF CANCER, 2024, 130 (10) : 1679 - 1686
  • [49] NSCLC Targeted Treatment of METex14 Skipping Gene Mutation
    Freye, Reimund
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 (1-2)
  • [50] Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISION
    Terufumi Kato
    James Chih-Hsin Yang
    Myung-Ju Ahn
    Hiroshi Sakai
    Masahiro Morise
    Yuh-Min Chen
    Ji-Youn Han
    Jin-Ji Yang
    Jun Zhao
    Te-Chun Hsia
    Karin Berghoff
    Rolf Bruns
    Helene Vioix
    Simone Lang
    Andreas Johne
    Xiuning Le
    Paul K. Paik
    British Journal of Cancer, 2024, 130 : 1679 - 1686
12345